Bristol-Myers Executive Accused of Insider Trading
He conducted due diligence on pension and savings plans of companies targeted for acquisition, including ZymoGenetics Inc., Pharmasset Inc. and Amylin Pharmaceuticals Inc., the FBI said. He bought options in all three, violating his duty to not profit from inside information, according to the FBI.